Insulet Corporation $PODD Stock Position Raised by Amundi

Amundi increased its holdings in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 13.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 507,847 shares of the medical instruments supplier's stock after acquiring an additional 60,929 shares during the quarter. Amundi owned approximately 0.73% of Insulet worth $77,320,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. California State Teachers Retirement System grew its holdings in Insulet by 13,901.9% in the 2nd quarter. California State Teachers Retirement System now owns 14,562,256 shares of the medical instruments supplier's stock worth $2,217,103,000 after buying an additional 14,458,254 shares in the last quarter. BlackRock Inc. bought a new position in shares of Insulet in the second quarter worth $1,018,582,000. Norges Bank acquired a new position in shares of Insulet during the fourth quarter valued at $300,794,000. Arrowstreet Capital Limited Partnership raised its stake in shares of Insulet by 462.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier's stock valued at $258,088,000 after purchasing an additional 1,011,369 shares in the last quarter. Finally, Man Group plc bought a new stake in shares of Insulet during the second quarter valued at about $78,746,000.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $152.00 price objective (down from $275.00) on shares of Insulet in a report on Thursday, August 6th. Robert W. Baird set a $175.00 target price on shares of Insulet in a research note on Thursday, August 6th. Bank of America dropped their price target on shares of Insulet from $288.00 to $208.00 and set a "buy" rating on the stock in a research report on Monday, May 18th. Wells Fargo & Company cut shares of Insulet from an "overweight" rating to an "equal weight" rating and decreased their price objective for the company from $255.00 to $144.00 in a report on Wednesday, August 5th. Finally, Sanford C. Bernstein lowered their price objective on shares of Insulet from $200.00 to $175.00 and set an "outperform" rating on the stock in a research note on Thursday, August 6th. Fourteen analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $195.40.

Insulet Trading Down 3.1%

Shares of NASDAQ:PODD opened at $137.92 on Thursday. The stock has a market capitalization of $9.56 billion, a price-to-earnings ratio of 25.78, a PEG ratio of 1.12 and a beta of 1.08. Insulet Corporation has a 1-year low of $126.40 and a 1-year high of $354.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. The company has a 50 day moving average price of $153.61 and a 200 day moving average price of $174.97.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.19. The company had revenue of $801.70 million for the quarter, compared to analysts' expectations of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The firm's revenue was up 23.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, research analysts anticipate that Insulet Corporation will post 6.51 EPS for the current fiscal year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.